{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:12:52Z","timestamp":1790813572051,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.leukres.2011.11.010","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T12:29:30Z","timestamp":1323865770000},"page":"311-315","source":"Crossref","is-referenced-by-count":10,"title":["Rituximab for the treatment of adult relapsed\/refractory CD20 positive B-ALL patients: A pilot series"],"prefix":"10.1016","volume":"36","author":[{"given":"Patrice","family":"Chevallier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Robillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Ayari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Eveillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Leguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.11.010_bib0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.11.010_bib0010","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.11.010_bib0015","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with Hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma ora cute lymphoblastic leucemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.11.010_bib0020","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and Rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leucemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.11.010_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00043426-200304000-00013","article-title":"Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with Rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation","volume":"25","author":"Corbacioglu","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.leukres.2011.11.010_bib0030","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2004.04925.x","article-title":"Rituximab in three children with relapsed\/refractory B-cell acute lymphoblastic leukaemia\/Burkitt non-Hodgkin's lymphoma","volume":"125","author":"De Vries","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.11.010_bib0035","article-title":"Optic nerve relapse in a child with common acute lymphoblastic leukemia, treated with a systemic anti-CD20 (Rituximab)","volume":"Suppl. 90","author":"Kraal","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.11.010_bib0040","first-page":"ECR23","article-title":"Fatal course after administration of Rituximab in a boy with relapsed ALL: a case report and review of literature","volume":"91","author":"Seifert","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.11.010_bib0045","first-page":"272","article-title":"Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia","volume":"91","author":"Claviez","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.11.010_bib0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2007.06814.x","article-title":"Remission induction with single agent Rituximab in a child with multiply relapsed precursor-B ALL","volume":"139","author":"Morris","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.11.010_bib0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of Rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.leukres.2011.11.010_bib0060","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1365-2141.2008.07497.x","article-title":"Effectiveness of intrathecal Rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy","volume":"144","author":"Jaime-Perez","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.11.010_bib0065","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.11305","article-title":"The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC rearrangement","volume":"92","author":"Le Gouill","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.11.010_bib0070","article-title":"First European chemotherapy schedule for elderly patients with acute lymphoblastic leukemia: promising remission rate and feasible moderate dose intensity consolidation","volume":"112","author":"Goekbuget","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2011.11.010_bib0075","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.11.010_bib0080","article-title":"First results of the GRAAPH-2005 study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia","volume":"112","author":"Chalandon","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2011.11.010_bib0085","article-title":"Results of the AFR07 prospective study in de novo Philadelphia positive ALL patients aged over 55 years: efficacy and safety of a Glivec\u00ae based induction followed by maintenance therapy with Glivec\u00ae and Pegasys\u00ae","volume":"110","author":"Rousselot","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2011.11.010_bib0090","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.11.010_bib0095","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood.V86.8.2922.2922","article-title":"The C5R Protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin'slymphoma of patients with no known cause of immunosuppression","volume":"86","author":"Blay","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.11.010_bib0100","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.11.010_bib0105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Practice & Research Clinical Haematology"},{"key":"10.1016\/j.leukres.2011.11.010_bib0110","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1182\/blood-2010-01-262006","article-title":"A mechanistic rationale for combining alemtuzumab and Rituximab in the treatment of ALL","volume":"116","author":"Nijmeijer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.11.010_bib0115","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/leu.2008.303","article-title":"Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases","volume":"23","author":"Chevallier","year":"2009","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611005601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611005601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T20:38:51Z","timestamp":1593376731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611005601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0145212611005601"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.11.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}